STOCK TITAN

Zai Lab (ZLAB) Financials

ZLAB NASDAQ
Trailing 12 months to September 30, 2026
Revenue $441.7M 0.0% YoY
Net Income -$198.4M n/m YoY
EPS (Diluted) -$0.19 n/m YoY per ordinary share, about -$1.90 per ADS
Free Cash Flow -$163.3M n/m YoY
Market Cap $2.8B as of Nov 18, 2026
Price / Sales 6.2x on $441.7M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 4.9x on $563.3M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. ZLAB trades in the US as American depositary shares (ADSs), and one ADS represents 10 ordinary shares.

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZLAB SEC filings page.

Zai Lab Limited (ZLAB) reported $441.7M in revenue over the twelve months to Sep 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZLAB FY2025

Zai Lab is growing revenue, but worsening gross economics and continued operating cash use leave the business loss-making.

Revenue rose 15.3%, while gross profit rose only 7.1%; this widening gap indicates growth is arriving with less contribution per sales dollar. The mechanism is visible in gross margin, which fell 4.5 percentage points from FY2024.

The cost base is becoming more efficient at the operating-expense level—SG&A and R&D both declined—but a $229M operating loss shows those reductions have not yet absorbed the gross-profit shortfall. Net loss narrowed to $176M, but the company remained materially loss-making.

Operating cash flow of -$151M was close to free cash flow of -$159M, indicating cash use came mainly from operations rather than unusually heavy capital spending. Meanwhile, liabilities rose 32.5% while the current ratio fell to 2.4x, shifting the financing profile toward more obligations relative to current assets.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 67 / 100
Financial Health Score 67/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Zai Lab Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
71

Zai Lab Limited held $689.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $150.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Zai Lab Limited scores 71/100 among other emerging companies.

Dilution
64

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Zai Lab Limited scores 64/100 on it among other emerging companies.

R&D Intensity
64

Zai Lab Limited spent $220.9M on research and development in fiscal year 2025, which was 32.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Zai Lab Limited scores 64/100 among other emerging companies.

Revenue Progress
72

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Zai Lab Limited scores 72/100 on it among other emerging companies.

Burn Trend
61

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Zai Lab Limited scores 61/100 on it among other emerging companies.

Balance Sheet
70

Zai Lab Limited's cash, cash equivalents and investments came to $689.6M at the end of fiscal year 2025, against $456.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Zai Lab Limited scores 70/100 among other emerging companies.

Altman Z-Score Distress
0.85

Zai Lab Limited scores 0.85, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $2.6B against total assets of $1.2B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

Zai Lab Limited passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Zai Lab Limited reported a net loss of $175.5M while operations used $150.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Zai Lab Limited reported an operating loss of $229.4M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$108.2M
YoY-6.8%
QoQ+1.8%
5Y CAGR+20.2%

Zai Lab Limited generated $108.2M in revenue in Q3 2026. This represents a decrease of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.

EBITDA
-$58.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Zai Lab Limited's EBITDA was -$58.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$46.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Zai Lab Limited reported a net loss of $46.1M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.04
YoYn/m
QoQn/m

Zai Lab Limited earned -$0.04 per diluted ordinary share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$58.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Zai Lab Limited recorded an outflow of $58.8M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$549.7M
YoY-23.4%
QoQ-9.5%
5Y CAGR-17.0%

Zai Lab Limited held $549.7M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
1.12B
YoY+1.7%
QoQ+0.2%

Zai Lab Limited had 1.12B ordinary shares outstanding in Q3 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
52.6%
YoY-7.1pp
QoQ-2.1pp

Zai Lab Limited's gross margin was 52.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 7.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.1 percentage points.

Operating Margin
-58.2%
YoY-16.1pp
QoQ+13.8pp

Zai Lab Limited's operating margin was -58.2% in Q3 2026, reflecting core business profitability. This is down 16.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.8 percentage points.

Net Margin
-42.6%
YoY-11.7pp
QoQ+5.2pp

Zai Lab Limited's net profit margin was -42.6% in Q3 2026, showing the share of revenue converted to profit. This is down 11.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.2 percentage points.

Return on Equity
-8.2%
YoY-3.5pp
QoQ+0.2pp
5Y change-2.1pp

Zai Lab Limited's quarterly ROE was -8.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

R&D Spending
$49.8M
YoY+3.9%
QoQ-19.4%

Zai Lab Limited invested $49.8M in research and development in Q3 2026. This represents an increase of 3.9% from the same quarter a year earlier. Against the prior quarter it is down 19.4%.

Capital Expenditures
$947K
YoY-68.5%
QoQ-27.7%
5Y CAGR-31.5%

Zai Lab Limited invested $947K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 68.5% from the same quarter a year earlier. Against the prior quarter it is down 27.7%.

Share Buybacks

Not reported for Q3 2026.

ZLAB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. ZLAB trades in the US as American depositary shares (ADSs), and one ADS represents 10 ordinary shares.

ZLAB quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$108.2M-6.8%$106.3M-3.3%$99.6M-6.5%$127.6M+17.0%$116.1M+13.5%$110.0M+9.4%$106.5M+22.2%$109.1M+65.7%
Cost of Revenue$51.3M+9.7%$48.2M+12.0%$38.3M-0.4%$62.3M+49.1%$46.8M+27.9%$43.0M+22.3%$38.5M+14.4%$41.8M+65.6%
Gross Profit$56.9M-17.9%$58.1M-13.2%$61.3M-9.9%$65.3M-3.0%$69.3M+5.5%$67.0M+2.5%$68.0M+27.1%$67.3M+65.8%
R&D Expenses$49.8M+3.9%$61.8M+22.0%$65.6M+8.0%$61.6M+18.0%$47.9M-27.4%$50.6M-17.9%$60.7M+11.1%$52.3M-36.2%
SG&A Expenses$70.1M0.0%$72.9M+2.6%$65.1M+2.6%$73.0M-11.6%$70.1M+4.3%$71.0M-10.9%$63.4M-8.3%$82.6M0.0%
Operating Income-$63.0Mn/m-$76.5Mn/m-$69.4Mn/m-$69.4Mn/m-$48.8Mn/m-$54.9Mn/m-$56.3Mn/m-$67.9Mn/m
EBITDA-$58.6Mn/m-$72.3Mn/m-$65.4Mn/m-$65.5Mn/m-$44.9Mn/m-$51.2Mn/m-$52.9Mn/m-$64.9Mn/m
Interest Expense$1.6M+12.6%$1.6M+25.8%$1.6M+37.9%$1.4M+50.4%$1.4M+87.9%$1.3M+156.5%$1.2M+950.4%$904Kn/m
Income Tax-$1.9Mn/m-$1.0Mn/m$1.4Mn/m-$2.9Mn/m$0n/m$0n/m$0n/m$0n/m
Net Income-$46.1Mn/m-$50.8Mn/m-$51.0Mn/m-$50.4Mn/m-$36.0Mn/m-$40.7Mn/m-$48.4Mn/m-$81.7Mn/m
EPS (Basic)-$0.04n/m-$0.05n/m-$0.05n/m-$0.05n/m-$0.03n/m-$0.04n/m-$0.04n/m-$0.08n/m
EPS (Diluted)-$0.04n/m-$0.05n/m-$0.05n/m-$0.05n/m-$0.03n/m-$0.04n/m-$0.04n/m-$0.08n/m
Diluted Shares (Avg)1.12B+1.9%1.12B+2.3%1.11B+2.5%N/A1.10B+12.3%1.09B+11.9%1.08B+11.1%N/A

ZLAB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZLAB quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.0B-11.7%$1.1B-7.7%$1.1B-6.6%$1.2B-1.1%$1.2B+17.6%$1.2B+17.9%$1.2B+18.7%$1.2B+14.4%
Current Assets$864.4M-16.3%$914.0M-11.6%$944.7M-9.3%$1.0B-3.0%$1.0B+20.0%$1.0B+18.9%$1.0B+17.2%$1.1B+11.8%
Cash & Equivalents$549.7M-23.4%$607.5M-17.0%$651.3M-14.0%$679.6M+51.1%$717.2M+16.4%$732.2M+16.2%$757.3M+16.4%$449.7M-43.1%
Short-Term Investments$10.0Mn/m$10.0Mn/m$10.0Mn/m$10.0M-97.0%$0n/m$0n/m$0n/m$330.0M+1924.5%
Inventory$85.3M+27.0%$90.9M+47.3%$86.0M+62.0%$74.7M+87.4%$67.1M+69.8%$61.7M+47.4%$53.1M+40.2%$39.9M-11.0%
Accounts Receivable$65.3M-23.5%$69.6M-21.4%$54.1M-29.4%$106.1M+24.6%$85.4M+70.9%$88.5M+27.1%$76.6M+26.7%$85.2M+43.9%
Long-Term Investments$0n/m$0n/m$0n/m$0-100.0%$0-100.0%$0-100.0%$0-100.0%$3.1M-66.2%
Total Liabilities$460.6M+15.4%$467.8M+25.6%$433.8M+19.6%$456.9M+32.5%$399.0M+25.6%$372.4M+31.5%$362.6M+60.2%$344.9M+43.6%
Current Liabilities$424.2M+17.9%$428.6M+29.3%$393.0M+22.9%$416.2M+39.0%$359.8M+25.7%$331.5M+31.7%$319.8M+66.5%$299.4M+47.4%
Non-Current Liabilities$36.4M-7.3%$39.2M-4.1%$40.8M-4.7%$40.7M-10.5%$39.2M+25.1%$40.9M+29.8%$42.8M+25.2%$45.5M+22.5%
Total Equity$563.3M-25.9%$607.0M-23.3%$662.0M-18.3%$715.5M-14.9%$759.9M+13.8%$791.7M+12.4%$810.8M+6.4%$840.9M+5.6%
Retained Earnings-$2.8Bn/m-$2.7Bn/m-$2.7Bn/m-$2.6Bn/m-$2.6Bn/m-$2.5Bn/m-$2.5Bn/m-$2.5Bn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ZLAB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZLAB quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$57.9Mn/m-$63.4Mn/m-$11.9Mn/m-$26.0Mn/m-$32.0Mn/m-$31.0Mn/m-$61.7Mn/m-$55.8Mn/m
Depreciation & Amortization$4.4M+13.1%$4.2M+11.7%$3.9M+14.1%$3.9M+29.2%$3.9M+35.9%$3.7M+27.0%$3.5M+14.8%$3.0M+23.3%
Stock-Based Compensation$11.3M-33.0%$12.1M-28.6%$13.5M-14.4%N/A$16.9M+0.8%$17.0M-8.9%$15.8M-12.1%N/A
Capital Expenditures$947K-68.5%$1.3M-54.6%$1.2M-22.1%$677K-74.0%$3.0M+123.9%$2.9M+289.3%$1.5M+57.5%$2.6M+1071.2%
Free Cash Flow-$58.8Mn/m-$64.7Mn/m-$13.1Mn/m-$26.7Mn/m-$35.0Mn/m-$33.9Mn/m-$63.2Mn/m-$58.4Mn/m
Investing Cash Flow-$12.7Mn/m-$1.4Mn/m-$22.3M-106.8%-$11.3Mn/m-$4.0Mn/m-$2.9Mn/m$326.1M+9806.8%-$347.8M-2505.4%
Financing Cash Flow$14.1M-32.4%$18.7M+111.4%$5.6M-87.1%-$430K-100.2%$20.8M-50.7%$8.8M-60.4%$43.1M-9.3%$237.8M+60412.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ZLAB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZLAB quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin52.6%-7.1pp54.7%-6.2pp61.5%-2.4pp51.2%-10.5pp59.7%-4.5pp60.9%-4.1pp63.9%+2.5pp61.7%0.0pp
Operating Margin-58.2%-16.1pp-72.0%-22.0pp-69.7%-16.8pp-54.4%+7.9pp-42.0%+24.3pp-49.9%+25.8pp-52.9%+27.8pp-62.3%
Net Margin-42.6%-11.7pp-47.8%-10.8pp-51.2%-5.7pp-39.5%+35.4pp-31.0%+9.8pp-37.0%+42.8pp-45.5%+15.9pp-74.9%
Return on Equity-8.2%-3.5pp-8.4%-3.2pp-7.7%-1.7pp-7.0%+2.7pp-4.7%+1.5pp-5.1%+6.3pp-6.0%+1.0pp-9.7%+2.3pp
Return on Assets-4.5%-1.4pp-4.7%-1.2pp-4.7%-0.5pp-4.3%+2.6pp-3.1%+1.1pp-3.5%+4.6pp-4.1%+1.3pp-6.9%+2.3pp
Current Ratio2.04-0.8x2.13-1.0x2.40-0.9x2.45-1.1x2.87-0.1x3.12-0.3x3.26-1.4x3.51-1.1x
Liabilities-to-Equity0.82+0.3x0.77+0.3x0.66+0.2x0.64+0.2x0.530.0x0.47+0.1x0.45+0.2x0.41+0.1x
Asset Turnover0.110.0x0.100.0x0.090.0x0.110.0x0.100.0x0.090.0x0.090.0x0.090.0x
FCF Margin-54.4%-24.2pp-60.9%-30.0pp-13.2%+46.2pp-20.9%+32.6pp-30.2%-2.7pp-30.8%+11.9pp-59.4%-53.5%-30.5pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Zai Lab Limited ZLAB FY2025 $460.2M -$175.5M -38.1% $2.8B 67/100
Legend Biotech Corporation LEGN FY2025 $1.0B -$296.8M -28.8% $3.2B 50/100
Viridian Therapeutics, Inc. VRDN FY2025 $70.8M -$342.6M N/A $3.4B 69/100
Dyne Therapeutics, Inc. DYN FY2025 N/A -$446.2M N/A $3.0B —
Telix Pharmaceuticals Limited TLX FY2025 $803.8M -$7.1M -0.9% $3.0B 44/100
IDEAYA Biosciences, Inc. IDYA FY2025 $218.7M -$113.7M -52.0% $2.6B 85/100

Frequently Asked Questions

Zai Lab Limited (ZLAB) reported $460.2M in total revenue for fiscal year 2025. This represents a 15.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Zai Lab Limited (ZLAB) revenue grew by 15.3% year-over-year, from $399.0M to $460.2M in fiscal year 2025.

No, Zai Lab Limited (ZLAB) reported a net loss of $198.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $175.5M, with a net profit margin of -38.1%.

Zai Lab Limited (ZLAB) reported diluted earnings per share of -$0.16 per ordinary share for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis. Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. ZLAB trades in the US as American depositary shares (ADSs), and one ADS represents 10 ordinary shares.

Zai Lab Limited (ZLAB) had EBITDA of -$214.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Zai Lab Limited (ZLAB) had a gross margin of 58.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Zai Lab Limited (ZLAB) had an operating margin of -49.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Zai Lab Limited (ZLAB) had a net profit margin of -38.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Zai Lab Limited (ZLAB) has a return on equity of -24.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Zai Lab Limited (ZLAB) recorded an outflow of $158.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Zai Lab Limited (ZLAB) recorded an outflow of $150.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Zai Lab Limited (ZLAB) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.

Zai Lab Limited (ZLAB) invested $8.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Zai Lab Limited (ZLAB) invested $220.9M in research and development during fiscal year 2025.

Zai Lab Limited (ZLAB) had 1.11B ordinary shares outstanding as of fiscal year 2025.

Zai Lab Limited (ZLAB) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.

Zai Lab Limited (ZLAB) had a liabilities-to-equity ratio of 0.64 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Zai Lab Limited (ZLAB) had a return on assets of -15.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Zai Lab Limited (ZLAB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $2.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Zai Lab Limited (ZLAB) trades at 6.2x sales, its market capitalization divided by $441.7M revenue, trailing 12 months to September 30, 2026. The market capitalization is $2.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Zai Lab Limited (ZLAB) held $689.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $150.8M over that year. Dividing the one by the other, the reported balance equals about 55 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Zai Lab Limited (ZLAB) has an Altman Z-Score of 0.85, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Zai Lab Limited (ZLAB) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Zai Lab Limited (ZLAB) reported a net loss of $175.5M while operations used $150.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Zai Lab Limited (ZLAB) reported an operating loss of $229.4M against $5.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Zai Lab Limited (ZLAB) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top